Janux Therapeutics Inc (NASDAQ: JANX)’s stock price has plunge by 3.44relation to previous closing price of 48.32. Nevertheless, the company has seen a 7.41% surge in its stock price over the last five trading sessions. zacks.com reported 2024-09-13 that Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
Is It Worth Investing in Janux Therapeutics Inc (NASDAQ: JANX) Right Now?
The 36-month beta value for JANX is at 3.57. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for JANX is 38.69M, and currently, shorts hold a 8.57% of that float. The average trading volume for JANX on September 20, 2024 was 593.16K shares.
JANX’s Market Performance
JANX stock saw an increase of 7.41% in the past week, with a monthly gain of 11.26% and a quarterly increase of 24.02%. The volatility ratio for the week is 6.62%, and the volatility levels for the last 30 days are 6.28% for Janux Therapeutics Inc (JANX). The simple moving average for the last 20 days is 9.59% for JANX stock, with a simple moving average of 45.18% for the last 200 days.
Analysts’ Opinion of JANX
Many brokerage firms have already submitted their reports for JANX stocks, with Stifel repeating the rating for JANX by listing it as a “Buy.” The predicted price for JANX in the upcoming period, according to Stifel is $70 based on the research report published on September 06, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see JANX reach a price target of $47. The rating they have provided for JANX stocks is “Sector Perform” according to the report published on May 30th, 2024.
BTIG Research gave a rating of “Buy” to JANX, setting the target price at $62 in the report published on March 21st of the current year.
JANX Trading at 15.77% from the 50-Day Moving Average
After a stumble in the market that brought JANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.81% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 6.62%, as shares surge +11.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.29% upper at present.
During the last 5 trading sessions, JANX rose by +7.41%, which changed the moving average for the period of 200-days by +452.88% in comparison to the 20-day moving average, which settled at $45.86. In addition, Janux Therapeutics Inc saw 365.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JANX starting from Lichter Jay, who proposed sale 3,815 shares at the price of $46.68 back on Sep 13 ’24. After this action, Lichter Jay now owns shares of Janux Therapeutics Inc, valued at $178,084 using the latest closing price.
Avalon BioVentures I, LP, the 10% Owner of Janux Therapeutics Inc, proposed sale 30,613 shares at $47.00 during a trade that took place back on Sep 12 ’24, which means that Avalon BioVentures I, LP is holding shares at $1,438,811 based on the most recent closing price.
Stock Fundamentals for JANX
Current profitability levels for the company are sitting at:
- -4.36 for the present operating margin
- 0.86 for the gross margin
The net margin for Janux Therapeutics Inc stands at -2.91. The total capital return value is set at -0.1. Equity return is now at value -9.20, with -8.53 for asset returns.
Based on Janux Therapeutics Inc (JANX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -1.95. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -20.13.
Currently, EBITDA for the company is -71.02 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 172.96. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 57.34.
Conclusion
In conclusion, Janux Therapeutics Inc (JANX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
